EnGeneIC

aka EnGeneIC Ltd

EnGeneIC is an Australian biotech that loads bacterially derived nanocells with chemotherapy and steers them to tumours with antibodies; E-EDV-D682 carries a super-cytotoxic payload to EGFR-expressing cancers.

EnGeneIC developed the EnGeneIC Dream Vector (EDV), a 400-nanometre bacterially derived minicell that is packed with a drug and coated with a bispecific antibody so it binds a tumour antigen and is taken up by the cancer cell. The EDVs also stimulate innate immunity. E-EDV-D682 targets EGFR and carries the PNU-159682 payload; it is being tested in pancreatic cancer and other advanced solid tumours, in some studies with immunomodulatory EDVs.

Headquarters

Sydney, AU

Scorecard

All companies

#398of 1181 companies, score 7

phase 1/2 +1
targets +2
modalities +2
registry trials +2

0 approved, 0 in phase 3, 1 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.

Type

biotech

Website

www.engeneic.com/

Founded

2001

Products

1top

Phase 2EDV nanocell (bacterial minicell) drug conjugate

E-EDV-D682

E-EDV-D682 is an experimental EDV nanocell (bacterial minicell) drug conjugate from Engeneic Pty in phase 2 trials for pancreatic ductal adenocarcinoma, aimed at EGFR.

Connected